Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Laxmi Organic Industries Ltd

LXCHEM
NSE
144.34
1.85%
Last Updated:
30 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Laxmi Organic Industries Ltd

LXCHEM
NSE
144.34
1.85%
30 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
4,001Cr
Close
Close Price
144.34
Industry
Industry
Chemicals - Organic
PE
Price To Earnings
49.94
PS
Price To Sales
1.42
Revenue
Revenue
2,821Cr
Rev Gr TTM
Revenue Growth TTM
-8.04%
PAT Gr TTM
PAT Growth TTM
-41.51%
Peer Comparison
How does LXCHEM stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
LXCHEM
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
730729652694792718771786710693700719
Growth YoY
Revenue Growth YoY%
-17.0-3.60.06.18.4-1.518.213.3-10.4-3.5-9.3-8.6
Expenses
ExpensesCr
672652613642702647697712651662663669
Operating Profit
Operating ProfitCr
587739529071757559313750
OPM
OPM%
7.910.66.07.511.49.99.79.58.34.45.37.0
Other Income
Other IncomeCr
7485812761643
Interest Expense
Interest ExpenseCr
-1521-13827567
Depreciation
DepreciationCr
232128283126273140172020
PBT
PBTCr
435618306854464713141626
Tax
TaxCr
18177224201818-9-740
PAT
PATCr
243811274434282922211125
Growth YoY
PAT Growth YoY%
-65.3-40.524.1-0.382.6-10.4162.37.8-50.9-37.7-60.8-13.3
NPM
NPM%
3.35.31.63.95.64.83.63.73.13.11.63.5
EPS
EPS
0.91.40.41.01.61.21.01.10.80.80.40.9

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
1,3761,5691,5341,7683,0842,7972,8652,9852,821
Growth
Revenue Growth%
14.0-2.215.374.4-9.32.44.2-5.5
Expenses
ExpensesCr
1,2241,4151,4211,5522,7162,5522,6092,7062,644
Operating Profit
Operating ProfitCr
151153114217368245256280177
OPM
OPM%
11.09.87.412.311.98.78.99.46.3
Other Income
Other IncomeCr
353051512282514
Interest Expense
Interest ExpenseCr
10171416151172025
Depreciation
DepreciationCr
31444947497210712497
PBT
PBTCr
113988115831817317116169
Tax
TaxCr
3825113161485047-11
PAT
PATCr
76727012725612512111480
Growth
PAT Growth%
-4.4-3.080.9101.8-51.4-3.3-5.8-29.9
NPM
NPM%
5.54.64.67.28.34.54.23.82.8
EPS
EPS
3.02.92.95.69.74.74.54.12.9

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
105045535353555555
Reserves
ReservesCr
3694003829821,2481,3591,7421,8511,873
Current Liabilities
Current LiabilitiesCr
4314605297689328308911,0521,114
Non Current Liabilities
Non Current LiabilitiesCr
84105113353417013885153
Total Liabilities
Total LiabilitiesCr
8951,0141,0691,8382,2682,4122,8273,0453,196
Current Assets
Current AssetsCr
5446256391,3051,4731,2171,4771,4111,213
Non Current Assets
Non Current AssetsCr
3513904315337951,1951,3501,6341,983
Total Assets
Total AssetsCr
8951,0141,0691,8382,2682,4122,8273,0453,196

Cash Flow

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
-718819610646199561108
Investing Cash Flow
Investing Cash FlowCr
-85-123-56-64174-384-490-268
Financing Cash Flow
Financing Cash FlowCr
85-63-123527-124232-4290
Net Cash Flow
Net Cash FlowCr
-7216-7-54730-70
Free Cash Flow
Free Cash FlowCr
-718819610647199561108
CFO To PAT
CFO To PAT%
-8.9259.2278.483.517.8159.7465.795.1
CFO To EBITDA
CFO To EBITDA%
-4.5122.4172.249.012.481.4219.538.6

Ratios

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
0004,59410,5335,9086,4914,856
Price To Earnings
Price To Earnings
0.00.00.036.141.147.453.942.8
Price To Sales
Price To Sales
0.00.00.02.63.42.12.31.6
Price To Book
Price To Book
0.00.00.04.48.14.23.62.5
EV To EBITDA
EV To EBITDA
1.20.60.819.428.525.324.717.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
29.630.128.933.631.533.732.834.8
OPM
OPM%
11.09.87.412.311.98.78.99.4
NPM
NPM%
5.54.64.67.28.34.54.23.8
ROCE
ROCE%
21.619.417.214.823.110.19.18.4
ROE
ROE%
20.016.116.412.319.78.86.76.0
ROA
ROA%
8.57.16.66.911.35.24.33.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
#### **Overview** Laxmi Organic Industries Ltd (LOIL), incorporated in 1989, is a leading Indian manufacturer of **Essential and Specialty Chemical Intermediates**, with a growing footprint in the global **fluorospecialties** space. It operates two core business segments: - **Essentials (Acetyl Intermediates)**: Lean, scale-driven supplier of large-volume industrial chemicals. - **Specialties (Specialty & Fluoro Intermediates)**: Innovation-led, high-margin segment focusing on complex chemistries and customized solutions. The company serves 750+ active customers across **55+ countries**, with a strong presence in pharmaceuticals, agrochemicals, paints & coatings, packaging, and high-performance materials. LOIL is evolving from a commodity chemical producer to a **technology-driven specialty chemicals leader**, underpinned by strategic acquisitions, robust R&D, and deep customer integration. --- ### **Strategic Outlook (Nov 2025)** #### **1. Market Position & Growth Strategy** - **Diketene Derivatives Market**: LOIL holds an **8–9% global market share** and is the largest product portfolio holder in this segment. It offers **over 40 diketene derivatives**, with 53% revenue share in India (2022–23 data). - **Fluorospecialties Expansion**: - LOIL is ramping up its fluorospecialties business post the **Miteni acquisition (2020)** from Italy, leveraging **electrochemical fluorination (ECF) technology**—a first in India. - The fluorination platform targets a **$2.5 billion global niche** within the broader $25 billion fluorination market, excluding commoditized segments like refrigerants and surfactants. - Revenues from fluorospecialties are expected to reach **40–50% of peak projections** in 2025, with full commercial ramp-up targeted by FY27–FY28. - **New Product Innovation**: Over **20% of revenue** is derived from products launched in the past five years, signaling a strong innovation pipeline and market responsiveness. #### **2. Key Strategic Initiatives and Projects** - **Hitachi Energy Partnership**: - A contract has been secured to produce **eco-efficient gas** for Hitachi’s **SF6-free high-voltage switchgear (EconiQ™)**. - Commercial production is underway in FY25, with capex covered under the **INR 1,100 crore consolidated investment plan**. - This project enhances LOIL’s positioning in sustainable power transmission and strengthens strategic partnerships with global leaders. - **Dahej Expansion (Greenfield Site)**: - A **70 KTA world-scale n-Butyl Acetate plant** is under development at the **86-acre Dahej (Gujarat)** site, designed for economies of scale and export readiness. - The new facility will **double ketene/diketene capacity** and serve North India and export markets. - Revenue contribution from Dahej is expected from **H2 FY26**, reaching peak levels by FY28. - **Lote Fluoro Intermediates Plant**: - Commercial production began in Q4 FY25, with 16 product approvals from customers. - The site can support up to **INR 400 crores** of future fluorine-related capex. #### **3. Innovation and R&D** - **R&D Infrastructure**: - LOIL operates a **30,000 sq. ft. Innovation Centre in Mahape, Navi Mumbai** (inaugurated Feb 2025), alongside a **2,500 sq. ft. R&D site in Mahad**. - Total R&D spend: **~2% of Specialties revenue**, with 15% of employees dedicated to R&D. - The team includes **67 chemists and 40+ engineers**, supported by kilo labs and pilot plants (100–1,800L reactor scale). - **Technology Platforms**: - Commercial-scale platforms in **diketene, ketene, ethylene oxide, mercaptans, and fluorination (ECF & HF)**. - Notable achievements: - Redesigned synthesis of a **pharma raw material**, improving end-product purity. - Scaled up **mercaptan chemistry** for a leading agrochemical innovator. - Developed **ethyl oxide derivatives** from lab to commercial scale for a global customer. - **Sustainability Focus**: - Offers **biobased Ethyl Acetate** with USDA Certified Biobased Product label. - **25% of power** comes from green sources (hydro, wind, solar). #### **4. Financial and Operational Highlights (FY25)** - **Revenue**: **INR 29.85 billion** in FY25. - **Growth Metrics**: - **11% volume growth** and **9.4% YoY EBITDA growth** driven by operational excellence and mix optimization. - **10%+ revenue growth** in Specialties, outpacing volume due to favorable mix and pricing. - **Cost Leadership**: - Operates at **full capacity** across assets; **top quartile on global cost curve** for Ethyl Acetate production. - Achieved **best-in-cost positioning** via scale, efficient logistics, and captive utilities. - **Capacity Expansion**: - **World’s first 70 KTA n-Butyl Acetate plant in India** being commissioned at Dahej (Q1 FY26). - **n-Propyl Acetate** (25 KTA) soft-launched from Mahad—100% import substitute. - **Balance Sheet & Capex**: - Unleveraged balance sheet enables future investments. - **INR 5,500–11,000 crore capex** planned between FY24–FY28 to: - Double revenue by **FY28** - Triple EBITDA - Achieve **20% RoCE** --- ### **Leadership & Organizational Strengths** - **Dr. Harsh Goenka (Promoter & Strategic Leader)**: - Led pivot from commodity to **specialty chemicals**, focusing on innovation, M&A, and sustainable value chains. - Advocate for **India’s self-reliance** in specialty chemicals. - **Core Management Team**: - **Salil Mukundan (CTO)**: 34 years in pharma/chemicals (IIT Bombay alum). - **Rajesh Naik (President - Manufacturing)**: 30 years, ex-BASF, DuPont; leading operational excellence. - **Susheel Mittal (CSO)**: 25+ years in global supply chains. - **Dr. Milind Vaidya (EVP - R&D & Specialties)**: 25+ years in R&D and market development. - **Global Structure**: Subsidiaries in **Europe (Netherlands), China, UAE, and USA**, enhancing export logistics and customer proximity. --- ### **Competitive Advantages** - **Technology Leadership**: Electrochemical fluorination, continuous fluorination, and proprietary diketene pathways. - **Scale & Integration**: - Backward integration via **two ethanol distilleries (Satara, Kolhapur)** and **co-gen power plants**. - Shared raw materials (acetic acid), infrastructure, and customer base across Essentials and Specialties. - **Customer-Centric Approach**: - Shift to **value chain integrator** and **custom solutions model**, increasing wallet share. - Reduced top-10 customer concentration to **26%**, indicating diversification. - **Operational Excellence**: - Use of **data analytics** to improve throughput; **operational efficiency** initiative delivering double-digit volume growth. - **Responsible Care Certified** and ISO-compliant sites (Mahad, Lote, Dahej). --- ### **Global Market Dynamics & Opportunities** - **Export Focus**: 30% of revenue from exports (mainly Europe, Middle East, Africa); **strategic storage in Rotterdam** for faster delivery. - **China+1 Tailwinds**: Global supply chain shifts are accelerating demand for Indian-made specialty chemicals. - **Fluorochemical Demand Drivers**: - Fluorine present in **1 in 3 new APIs** and **50% of new agrochemicals**. - Strong customer pull for **import-substituted fluoro-chemicals**, reducing foreign exchange exposure. - **Sustainability Shift**: Demand for **green solvents** and **SF6-free gas alternatives** aligns with LOIL’s offerings.